Thank you for standing by, and welcome to the Trevi Therapeutics, Inc annual meeting. I will now turn the meeting over to David Meeker, Chairman of the Board of Directors at Trevi. Please go ahead. Thank you. Good morning, and welcome to the 2026 annual meeting of stockholders of Trevi Therapeutics. I am David Meeker, Chairman of the Board of Directors of Trevi, and I will be presiding over this meeting. I welcome you all and call the meeting to order. Before we get to the formal business of the meeting, I would like to make some introductions. Joining us at the meeting today are the other directors of the company, Jennifer Good, Trevi's President and Chief Executive Officer, Nick Colangelo, Michael Heffernan, Edward Mathers, and Anne VanLent. Also joining us are the other officers of the company, Dr. James Cassella, Chief Development Officer, David Hastings, Chief Financial Officer and Treasurer, Dr. Thomas Sciascia, Chief Scientific Officer, Dr. Farrell Simon, Chief Commercial Officer, and Christopher Galletta, Controller and Corporate Secretary. I would also like to introduce Stuart Falber of WilmerHale, our outside legal counsel, Chiara Ciraldo, a partner from Ernst & Young LLP, our independent registered public accounting firm, and Jennifer Borden of Borden Consulting Group LLC, the company's Inspector of Elections for this meeting. I will now turn the meeting over to Jennifer to conduct the formal portion of the meeting. In order to conduct an orderly meeting, I call your attention to the rules of conduct posted on the virtual meeting website, which includes information about participating in the meeting, including asking questions. Please note that various remarks we may make about future expectations, plans, and prospects for the company constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recently filed annual report on Form 10-K, which is on file with the SEC. In addition, these forward-looking statements represent the company's expectations only as of today. While the company may elect to update these forward-looking statements, it specifically disclaims any obligation to do so. Any forward-looking statements should not be relied upon as representing the company's estimates or views as of any date subsequent to today. I received an affidavit from the company's tabulator, Broadridge Financial Solutions, certifying that the notice of the annual meeting and the proxy statement were sent to all stockholders of record as of April 6th, 2026, a copy of which will be attached to the minutes of the meeting. Our first order of business at this meeting is to determine whether the shares represented at this meeting, either in person via this virtual meeting or by proxy, are sufficient to constitute a quorum for the purpose of transacting business. Holders of 128,586,792 shares of common stock are entitled to vote at this meeting. The inspector of election has informed me that there are present at this meeting, either in person or by proxy, a total of 114,343,895 shares of common stock, or approximately 88.92% of all shares entitled to vote at this meeting. Therefore, I declare that a quorum exists. Turning now to the items to be voted on at this meeting. As indicated in the notice of meeting and accompanying documents that were made available to stockholders, the first matter to be voted on is the election of one Class I director to serve until the 2029 annual meeting of stockholders and until his successor is duly elected and qualified. The nominee for election is Michael Heffernan. The second matter to be voted on is the ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the current fiscal year ending December 31, 2026. The third matter to be voted on is the approval on an advisory basis of the compensation paid to our named executive officers. The fourth matter to be voted on is the approval of the Trevi Therapeutics, Inc amended and restated 2019 stock incentive plan. The final matter to be voted on is the approval of an amendment to the Trevi Therapeutics, Inc restated certificate of incorporation, as amended, to increase the number of authorized shares of common stock from 200 million to 400 million shares. If there are any questions on the proposal, they may be submitted on the virtual meeting website. I remind you that there will be an opportunity for general questions not related to the proposals after the formal portion of the meeting has concluded. To ask a question, please submit it using the Ask A Question box on the meeting portal of the virtual meeting website. Seeing no questions, we'll move on to voting on the proposals. I hereby declare the polls are now open for each matter to be voted upon today. If you have not yet voted, or if you previously voted by proxy and wish to change your vote, you may do so by following the instructions on the virtual meeting website. We will pause briefly to allow stockholders to vote. Now that everyone has had an opportunity to vote, the business items on the agenda for this meeting are complete, and the polls are now closed. Will Jennifer Borden please tabulate the votes? We now have the preliminary report of the results of the voting. The nominee for director has been elected as a Class I director. The appointment of Ernst & Young LLP has been ratified. The compensation paid to our named executive officers has been approved. The Trevi Therapeutics, Inc amended and restated 2019 stock incentive plan has been approved, and the amendment to the Trevi Therapeutics, Inc restated certificate of incorporation, as amended, to increase the number of authorized shares of common stock from 200 million shares to 400 million shares, has been approved. The final vote results will be included in a Form 8-K that'll be filed within four business days after this meeting. As there are no further business to come before the meeting, I declare the formal part of this meeting adjourned. We will now use our remaining available time to answer appropriate questions from stockholders. Please follow the instructions provided on the virtual meeting website to submit questions. Seeing no questions, we will end our annual meeting. Thank you for attending. This concludes today's meeting. You may now disconnect.